Targets › SCTR
2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 4; Oncology, Gastroenterology; next expected readout Mar 2027.
G protein-coupled receptor activated by secretin (SCT), which is involved in different processes such as regulation of the pH of the duodenal content, food intake and water homeostasis. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and activates cAMP-dependent pathway. (UniProt, P47872)
Open in Phaseline: the race on SCTR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mayo Clinic | Secretin (human synthetic) - ChiRhoClin Secretin receptor agonist | SCTR | Phase 4 | Exocrine Pancreatic Insufficiency | Mar 2027 |
| Johns Hopkins University | Secretin Synthetic Human Secretin receptor agonist | SCTR | Phase 3 | Pancreas Cancer | Dec 2028 |
Pancreas Cancer (1) Exocrine Pancreatic Insufficiency (1)
small molecule (2)
Johns Hopkins University (1) Mayo Clinic (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.